Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Normal and pathological lipoprotein metabolism.

G R Thompson1

  • 1Hammersmith Hospital, London, United Kingdom.

Drugs
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Hyperlipidaemia, characterized by increased lipoproteins, stems from various physiological and pathological factors. Understanding inherited forms like familial hypercholesterolaemia (FH) and familial combined hyperlipidaemia (FCH) is crucial for managing atherosclerosis risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multicenter Registry of Patients Receiving Systemic Mold-Active Triazoles for the Management of Invasive Fungal Infections.

Infectious diseases and therapy·2022
Same author

Coccidioidomycosis in llamas and alpacas diagnosed at the University of California, Davis (1990-2016).

Medical mycology·2020
Same author

Ibrexafungerp: A novel oral glucan synthase inhibitor.

Medical mycology·2019
Same author

A microbiome assessment of medical marijuana.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2016
Same author

The Nobel dilemma: to reward scientific discovery or benefit to mankind?

QJM : monthly journal of the Association of Physicians·2015
Same author

Dyslipidaemia and the military patient.

Journal of the Royal Army Medical Corps·2015
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Lipid metabolism and cardiovascular disease.
  • Genetics and inherited metabolic disorders.

Background:

  • Hyperlipidaemia involves elevated plasma lipoproteins, contributing to various health conditions.
  • Physiological factors (age, diet) and pathological factors (genetics, disease) influence lipoprotein levels.

Purpose of the Study:

  • To elucidate the distinct metabolic defects in three inherited hyperlipidaemia forms predisposing to atherosclerosis.
  • To explain the mechanisms behind familial hypercholesterolaemia (FH), type III hyperlipoproteinaemia, and familial combined hyperlipidaemia (FCH).

Main Methods:

  • The study focuses on the underlying metabolic defects in specific inherited hyperlipidaemia types.
  • Analysis of lipoprotein metabolism, receptor function, and particle synthesis.

Related Experiment Videos

Main Results:

  • Familial hypercholesterolaemia (FH) results from LDL receptor deficiency, causing LDL-cholesterol accumulation.
  • Type III hyperlipoproteinaemia involves abnormal apo E2, leading to remnant particle accumulation due to impaired hepatic uptake.
  • Familial combined hyperlipidaemia (FCH) shows increased VLDL and LDL due to enhanced synthesis, not a primary catabolic defect.

Conclusions:

  • Distinct genetic defects drive different forms of hyperlipidaemia, impacting atherosclerosis risk.
  • Understanding these specific metabolic pathways is key for targeted therapeutic strategies.